LXEO
Lexeo Therapeutics, Inc. Common Stock
NASDAQ: LXEO · HEALTHCARE · BIOTECHNOLOGY
$5.70
+0.26% today
Updated 2026-04-30
Market cap
$416.74M
P/E ratio
—
P/S ratio
478.26x
EPS (TTM)
$-1.86
Dividend yield
—
52W range
$2 – $11
Volume
0.9M
Lexeo Therapeutics, Inc. Common Stock (LXEO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $518476.00 | $1.66M | $654000.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | +219.6% | -60.5% | -100.0% | — | — |
| Cost of revenue | — | $13405.00 | $1.15M | $1.84M | $2.00M | $2.08M |
| Gross profit | $518476.00 | $1.66M | $654000.00 | $-1.84M | $-2.00M | $-2.08M |
| Gross margin | 100.0% | 100.0% | 100.0% | — | — | — |
| R&D | $4.32M | $45.12M | $49.16M | $53.13M | $74.09M | $63.80M |
| SG&A | $787499.00 | $7.17M | $12.00M | $15.38M | $31.68M | $45.46M |
| Operating income | $-4.59M | $-50.64M | $-60.51M | $-68.51M | $-105.77M | $-109.26M |
| Operating margin | -884.9% | -3055.9% | -9252.1% | — | — | — |
| EBITDA | $-4.59M | $-50.61M | $-58.04M | $-64.35M | $-96.19M | $-107.18M |
| EBITDA margin | -884.9% | -3054.3% | -8874.8% | — | — | — |
| EBIT | $-4.59M | $-50.62M | $-59.19M | $-66.19M | $-98.20M | $-109.26M |
| Interest expense | $147150.00 | $0.00 | $91000.00 | $205000.00 | $114000.00 | $206000.00 |
| Income tax | $147150.00 | $-155.00 | $89000.00 | $-1.00 | — | — |
| Effective tax rate | -2.9% | 0.0% | -0.2% | 0.0% | 0.0% | 0.0% |
| Net income | $-5.15M | $-50.62M | $-59.28M | $-66.39M | $-98.33M | $-99.96M |
| Net income growth (YoY) | — | -882.4% | -17.1% | -12.0% | -48.1% | -1.7% |
| Profit margin | -993.8% | -3055.0% | -9063.8% | — | — | — |